Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc

The total consolidated income of the company has increased by 21.17% at Rs 3,959.67 crore for Q4FY26

The Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of around $37.9 million

Glenmark’s Progesterone Vaginal Inserts, 100 mg will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

The expected weekly cost of treatment with GLIPIQ vials range from Rs 325 to Rs 440, significantly lowering the cost barrier to initiate GLP-1 therapy in India

Fluticasone Propionate Nasal Spray USP, 50 mcg per spray will be distributed in the U.S. by Glenmark Therapeutics Inc., USA

The Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market achieved annual sales of around $102.9 million

Glenmark Pharmaceuticals Inc., USA is all set to launch of Potassium Phosphates Injection in March 2026

Glenmark’s Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026

Glenmark will begin distribution in April 2026

Glenmark’s Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label

Glenmark Specialty S.A. has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co

The Leucovorin Calcium for Injection, 350 mg/vial market achieved annual sales of around $16.8 million

The inspection was carried out from November 24, 2025 to November 28, 2025, and concluded with zero 483 observations

The commercial manufacturing at the Monroe site will now restart

The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD

With receipt of this approval, Glenmark will initiate commercializing Winlevi across 15 countries in EU

Commercialization in China will be undertaken by Grand Pharmaceuticals Group under an exclusive licensing agreement

Glenmark will begin distribution in November 2025

Glenmark will begin distribution in November 2025

Glenmark Pharmaceuticals Inc has initiated the Class II nationwide recall on September 17, 2025

Under the terms of the agreement, Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide

The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing in the country

The company will begin distribution in September 2025

Pursuant to this, the company now holds 32.95% stake in O2 Renewable Energy XXIV

The company will begin distribution in September 2025

The total consolidated income of the company increased by 0.46% at Rs 3290.88 crore for Q1FY26

The U.S. FDA had inspected the Glenmark’s Indore site from February 03, 2025 to February 14, 2025

AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China

This launch marks Glenmark’s first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio

At the end of the inspection, the Company was issued a Form 483 with five observations

Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA

The total consolidated income of the company decreased by 14.81% at Rs 3,267.89 crore for Q4FY25

The company will begin distribution in May 2025

It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets

The company initiated the Class II nationwide (US) recall on March 11, 2025

The Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of around $39.3 million

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk

The MiraLAX Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million

The company is recalling the affected lot due to ‘CGMP Deviations’

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc

The company’s Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug

Total consolidated income of the company increased by 33.96% at Rs 3418.68 crore for Q3FY25

The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million

According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million

The Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million

Diltiazem Hydrochloride extended-release capsules are used to treat high blood pressure

Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc.

The Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.

Additionally, Glenmark Pharmaceuticals Inc, US, is also recalling 11,568 tubes of Ciclopirox Gel

The inspection closed with no observation

Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization in India

The newly formed IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors currently undergoing clinical trials

GSSA will receive from Jiangsu Alphamab and 3DMed, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.

Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70%, and will be available only under prescription

The product is used to treat hemochromatosis, or iron overload in the blood

Glenmark’s current portfolio consists of 189 products authorized for distribution in the U.S. marketplace and 50 ANDA’s pending approval with the USFDA

This FDC has been launched under the brand name Zita DM

Glenmark’s current portfolio consists of 188 products authorized for distribution in the U.S. marketplace

With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases

Cosmo will be the exclusive supplier of the product

Glenmark Pharma will own 7.84% in GLS after the divestment

The company is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology

The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm

Glenmark’s current portfolio consists of 184 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA

The collaboration aims to raise awareness on measuring blood pressure at home from the age of 18

The Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of around $100.7 million

The USFDA had conducted the inspection at said facility between April 04 to May 19, 2022

This price reduction will bring the per mg cost of Trumab to around Rs 35

The company has incorporated wholly-owned subsidiary to carry out manufacturing and trading of Pharmaceutical products

Under these settlements, the company plans to pay $48 million to the Direct Purchaser Plaintiffs

With this approval, Glenmark is eligible for 180-days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam

Glenmark’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

GRC 54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark

Glenmark’s Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

Glenmark expects to commence distribution of the product in the U.S. during the second half of 2023

Glenmark’s first tentative approval letter for Saxagliptin Tablets, 2.5 mg and 5 mg was received on June 12, 2017

Total consolidated income of the company increased by 11.07% to Rs 3540.27 crore for Q3FY23

The drug is already being marketed in the EU, the US, and Australia

The divested Tail Brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands

The sacubitril-valsartan combination belongs to the class ARNI

Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

Glenmark’s Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

This divestment is in line with Glenmark’s strategy of focusing on other sub-categories of the cardio-vascular segment

USFDA pointed out various lapses at the company’s Bardez-based facility in Goa, which produces drug formulations

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA

Total consolidated income of the company increased by 10.79% to Rs 3,472.68 crore for Q2FY23

Glenmark’s current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the USFDA

Glenmark’s current portfolio consists of 176 products authorized for distribution in the U.S. marketplace

Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg)

The results of this trial have shown a faster and improved glycemic control with Lobeglitazone

The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose

The company’s North American business, including the US, recorded a revenue of Rs 662.8 crore in April-June 2022

The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year

The affected lot has been manufactured in India and distributed in the US by Glenmark Pharmaceuticals Inc

Minym Gel (Topical Minocycline 4% Gel) has been developed to address growing concerns in treatment of acne and is safe to use in patients above 9 years of age

The company has introduced 8 different combinations of sitagliptin based drugs under the brand name SITAZIT and its variants at affordable price

The company is committed to undertake all necessary steps required to address their observation at the earliest

This platform is patient friendly and will be available in 6 different regional languages including Hindi and English, enabling better patient compliance to the technology